NCT07288801 Vitamin D for Preventing Recurrent Preeclampsia in Pregnant Women
| NCT ID | NCT07288801 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Nishtar Medical University |
| Condition | Pre-eclampsia |
| Study Type | INTERVENTIONAL |
| Enrollment | 146 participants |
| Start Date | 2025-08-09 |
| Primary Completion | 2026-02-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 146 participants in total. It began in 2025-08-09 with a primary completion date of 2026-02-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to find out whether giving vitamin D to pregnant women who had pre-eclampsia in a previous pregnancy helps prevent the condition from coming back. The main question it aims to answer is: Does vitamin D supplementation reduce the chance of pre-eclampsia recurring in pregnant women with a history of pre-eclampsia? To answer this question, pregnant women attending the antenatal clinic at the Department of Obstetrics and Gynaecology, Nishtar Hospital Multan will be invited to join the study. Participants will be randomly assigned to two equal groups: * Vitamin D group: will take 4,000 IU of oral vitamin D until 36 weeks of gestation. * Placebo group: will receive a pill identical in appearance, taste, and consistency but without vitamin D. While on the study medication, each woman will visit the clinic every two weeks. At each visit, her blood pressure will be measured, and if it is 140/90 mmHg or higher, a urine test will check for protein to identify pre-eclampsia as per hospital protocol. Any diagnosis of pre-eclampsia will lead to standard care, and the outcome will be recorded. At the end, researchers will compare how many women in each group developed recurrent pre-eclampsia. This study will help answer whether vitamin D supplementation can safely reduce the risk of pre-eclampsia returning in women with a prior history - a question important for improving pregnancy outcomes and maternal health.
Eligibility Criteria
Inclusion Criteria: * Gestational age ≥ 20-weeks (on LMP method) ' - Past medical history of pre-eclampsia Exclusion Criteria: * Pre-existing hypertension, cardiac diseases, renal disease, thyrotoxicosis (on history and medical record) * Women presenting with intra-uterine death of the fetus.
Contact & Investigator
Mehnaz K Professor, FCPS
STUDY CHAIR
Nishtar Medical University and Hospital
Frequently Asked Questions
Who can join the NCT07288801 clinical trial?
This trial is open to female participants only, aged 20 Years or older, up to 45 Years, studying Pre-eclampsia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07288801 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07288801 currently recruiting?
Yes, NCT07288801 is actively recruiting participants. Contact the research team at tehseenaslam451@gmail.com for enrollment information.
Where is the NCT07288801 trial being conducted?
This trial is being conducted at Multan, Pakistan.
Who is sponsoring the NCT07288801 clinical trial?
NCT07288801 is sponsored by Nishtar Medical University. The principal investigator is Mehnaz K Professor, FCPS at Nishtar Medical University and Hospital. The trial plans to enroll 146 participants.